AMT Gets $3.2M Runway, Aims For Hemophilia Gene Therapy
BioWorld International Correspondent
LONDON – The venture capital investors in Amsterdam Molecular Therapeutics (AMT) have thrown it a €2.5 million (US$3.2 million) lifeline in the hope that will enable the company to stay solvent long enough to close a deal for its gene therapy treatment for hemophilia B.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST